RESUMEN
Clinically "non-functioning" human pituitary adenomas (NFPA) constitute about 35% of pituitary adenomas. Somatostatin receptors (SSTR) expression in these adenomas has previously been described both in vitro and in vivo, without evidence for a correlation with tumor volume or the therapeutic efficacy of somatostatin analogs. This study was performed on 13 surgically removed pituitary macroadenomas, diagnosed before surgery as "non-functioning". In addition, 3 growth hormone (GH)-secreting adenomas served as controls. A specimen from each tumor was dispersed and digested to isolate and culture the tumor cells, and the in vitro effects of SSTR2 and SSTR5 selective analogs and Cortistatin (CST) (100nM) on cell viability were studied. The quantity of viable cells was estimated using the XTT method. RNA purification of tumor samples and subsequent RT-PCR studies for SSTR2 and SSTR5 expression were performed. Somatostatin analog with high affinity for SSTR2 reduced cell viability by 20-80% in 8 of 13 NFPAs studied, all expressing the SSTR2. The inhibitory effect on cell viability of SSTR5-selective analog was 15-80% in 10 of 13 NFPAs studied, all but three expressing the SSTR5. CST, however, effectively reduced cell viability in only 6 NFPAs. Cell viability was inhibited by all peptides studied in 2 out of 3 GH-secreting adenomas, expressing both receptors. The third adenoma responded to SSTR2 analog and expressed only SSTR2. These results suggest the involvement of SSTR2 and SSTR5 in the anti-proliferative effects of somatostatin; however, CST is less potent in reducing cell viability in these tumors.
Asunto(s)
Adenoma/patología , Antineoplásicos Hormonales/farmacología , Neoplasias Hipofisarias/patología , Somatostatina/análogos & derivados , Somatostatina/farmacología , Adenoma/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Supervivencia Celular/efectos de los fármacos , Ensayos de Selección de Medicamentos Antitumorales , Femenino , Adenoma Hipofisario Secretor de Hormona del Crecimiento/metabolismo , Adenoma Hipofisario Secretor de Hormona del Crecimiento/patología , Hormona de Crecimiento Humana/metabolismo , Humanos , Masculino , Persona de Mediana Edad , Neuropéptidos/farmacología , Péptidos Cíclicos/farmacología , Neoplasias Hipofisarias/metabolismo , Células Tumorales CultivadasRESUMEN
Hyponatremia associated with high urine osmolality is usually caused by inappropriate secretion of antidiuretic hormone. However, secondary hypoadrenalism is also accompanied by hyponatremia and with features indistinguishable from the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). As secondary hypoadrenalism requires a specific treatment, a high index of suspicion and appropriate hormonal testing are required to differentiate between these two entities. We retrospectively studied 10 patients with a previously undiagnosed hypothalamic-pituitary disease who presented with an acute symptomatic hyponatremia. Mean age (+/-SD) was 65.1+/-8.4 yr. Mean serum sodium was 120.7+/-2.9 nmol/l and urinary osmolality, 453.9+/-74 mosmol/kg. Serum creatinine, urea and uric acid were low. Mean serum morning cortisol was low, 104.0+/-55.2 nmol/l. High-dose ACTH test showed adequate increment of serum cortisol in 3 out of 7 patients tested. Two of these 3 patients did not respond adequately to the low-dose ACTH test. Endocrine evaluation disclosed partial or complete hypopituitarism in all 10 patients. Six patients had pituitary macroadenomas, one had a craniopharyngioma, one patient had a large aneurysm of the internal carotid with sellar destruction and two others had empty sella. Treatment by fluid restriction did not affect serum sodium levels significantly. In contrast, all patients achieved normal sodium when treated by glucocorticosteroid. Central hypoadrenalism should be considered in any patient presenting with hyponatremia with high urine osmolality. Low-dose ACTH test should be performed and followed by appropriate endocrine and imaging studies. Hyponatremia in these patients is promptly corrected by glucocorticosteroid replacement.
Asunto(s)
Glucocorticoides/uso terapéutico , Hiponatremia/tratamiento farmacológico , Hiponatremia/etiología , Enfermedades Hipotalámicas/complicaciones , Síndrome de Secreción Inadecuada de ADH/complicaciones , Enfermedades de la Hipófisis/complicaciones , Hormona Adrenocorticotrópica/administración & dosificación , Anciano , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Hidrocortisona/sangre , Enfermedades Hipotalámicas/sangre , Enfermedades Hipotalámicas/diagnóstico , Síndrome de Secreción Inadecuada de ADH/sangre , Síndrome de Secreción Inadecuada de ADH/diagnóstico , Masculino , Persona de Mediana Edad , Enfermedades de la Hipófisis/sangre , Enfermedades de la Hipófisis/diagnóstico , Estudios RetrospectivosRESUMEN
BACKGROUND: Pituitary apoplexy is a rare major clinical event with neurological, neuro-ophthalmological, cardiovascular and hormonal consequences, resulting from an acute infarction of pituitary adenoma. We report our experience with a series of 40 patients presenting with pituitary apoplexy. PATIENTS: Forty patients (27 males, 13 females; mean age, 51.2 yr) were admitted to our medical center between years 1985-2002 with acute presentation of pituitary apoplexy. Visual field defects occurred in 61% and ocular paresis in 40% of subjects. Sixty-three percent of adenomas were nonfunctional, and prolactinomas comprised 31%. RESULTS: Thirty-four patients underwent transsphenoidal pituitary decompression. Visual fields and ophthalmoplegia improved in 81% and 71%, respectively. During follow-up (4.5+/-5.4 yr), 79% of patients developed hypogonadotrophic hypogonadism, central hypothyroidism appeared in 54% and hypocortisolism--in 40% of patients. Permanent diabetes insipidus was diagnosed in 8%. Serial sellar MRI showed disappearance of pituitary tumor in 63% of operated subjects. Six patients (3 with PRL-secreting and 3 nonfunctional adenomas) were treated medically (corticosteroids, dopamine agonists), two patients (out of three) with visual deficits improved, and tumor shrinkage was noted in four. CONCLUSIONS: We present a large series of patients with pituitary apoplexy. Most subjects were operated, but six were treated conservatively. Almost all patients improved clinically, including those who were not operated, but hormonal deficiencies are very common.
Asunto(s)
Adenoma/complicaciones , Descompresión Quirúrgica/métodos , Procedimientos Neuroquirúrgicos/métodos , Apoplejia Hipofisaria/complicaciones , Apoplejia Hipofisaria/cirugía , Neoplasias Hipofisarias/complicaciones , Adolescente , Corticoesteroides/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , Protocolos Clínicos , Descompresión Quirúrgica/estadística & datos numéricos , Agonistas de Dopamina/uso terapéutico , Femenino , Humanos , Hipopituitarismo/etiología , Hipopituitarismo/fisiopatología , Hipopituitarismo/cirugía , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Procedimientos Neuroquirúrgicos/estadística & datos numéricos , Quiasma Óptico/fisiopatología , Quiasma Óptico/cirugía , Nervio Óptico/fisiopatología , Nervio Óptico/cirugía , Apoplejia Hipofisaria/fisiopatología , Hipófisis/patología , Hipófisis/fisiopatología , Hipófisis/cirugía , Estudios Retrospectivos , Hueso Esfenoides/patología , Hueso Esfenoides/cirugía , Resultado del Tratamiento , Baja Visión/etiología , Baja Visión/fisiopatología , Baja Visión/cirugíaRESUMEN
OBJECTIVE: Ghrelin, a recently identified 28-amino acid peptide is a potent GH secretagogue (GHS) produced predominantly by the stomach. Ghrelin stimulates GH secretion through binding to the GHS receptor in the hypothalamus and pituitary. In addition to the GH-releasing action, ghrelin has been found to be a powerful orexigenic factor. To assess the direct in vitro effects of ghrelin on human pituitary hormone secretion we have produced a panel of novel ghrelin analogs (molecular weight, 3323-3384; human native ghrelin, 3371) with enhanced affinity for the human GHS receptor (IC(50) 0.38-1.09 nM; human ghrelin, 1.2-2.2 nM). METHODS: The peptidic analogs were tested for their effect on GH secretion using dispersed human fetal pituitaries (21 to 23 weeks of gestation) and cultured GH- and prolactin (PRL)-secreting adenomas. The expression of the GHS receptor in normal (fetal and adult) human pituitary tissues, GH- and PRL-cell adenomas was established using RT-PCR. RESULTS: The effects of ghrelin, its analogs and GH-releasing hormone (GHRH) alone or in combination on GH and PRL secretion were compared at various concentrations. The ghrelin analogs stimulated GH release by 35-60% from human fetal pituitary cells (1-10 nM; P<0.05) and by 50-75% from cultured pituitary adenomas (10 nM; P<0.05). This releasing effect was dose-dependent, achieving maximal stimulation with analog concentrations at 100 nM. Human ghrelin was less potent as compared with its analogs in stimulating human GH, in keeping with the improved binding affinity of the analogs for the GHS-1a receptor. The ghrelin analogs and GHRH had comparable effects on GH secretion from both normal and adenomatous cells, and in combination produced an additive stimulatory effect on GH (150%; P<0.0001). In contrast, ghrelin and its analogs induced a comparable increase in PRL release ranging between 25 and 40% (P<0.05) from fetal cells and 30 and 70% (P<0.001) from cultured PRL-cell and mixed GH-PRL adenomas. CONCLUSIONS: Our results have demonstrated for the first time that ghrelin analogs with enhanced affinity for the GHS receptor are potent stimulators of GH secretion from human pituitary cells, and thus may possess potential clinical therapeutic benefits.
Asunto(s)
Hormona de Crecimiento Humana/metabolismo , Hormonas Peptídicas/farmacología , Hipófisis/metabolismo , Prolactina/metabolismo , Receptores Acoplados a Proteínas G/efectos de los fármacos , Adenoma/metabolismo , Células Cultivadas , Ghrelina , Humanos , Ligandos , Hipófisis/citología , Hipófisis/efectos de los fármacos , Neoplasias Hipofisarias/metabolismo , ARN/biosíntesis , ARN/aislamiento & purificación , Receptores de Ghrelina , Reacción en Cadena de la Polimerasa de Transcriptasa InversaRESUMEN
SS, a natural cyclic tetradecapeptide, is a potent suppressor of pituitary GH and TSH secretion. At least five distinct SS receptor (SSTR) subtypes have been cloned and termed SSTRs 1-5. Both SSTR2 and SSTR5 regulate human GH and TSH secretion. Recently, a novel enzymatically stable SS analog, PTR-3173 (Somatoprim), with affinity for human SSTR2, SSTR4 and SSTR5, has been identified. This cyclic heptapeptide analog suppressed rat GH in vivo with no effect on insulin and minimal effect on glucagon secretion. Using primary cultures of human fetal pituitaries (20-24-week gestation) and GH-secreting adenomas, we studied the in vitro inhibitory effects of PTR-3173 on human pituitary secretion. PTR-3173 suppressed GH release from both fetal pituitaries (maximal suppression of 54% with 10 nM) and cultures of GH-cell adenomas (35% suppression with 100 nM). Octreotide and PTR-3173 had comparable inhibitory effects on GH secretion from fetal human pituitaries. TSH was mildly suppressed by PTR-3173, whereas ACTH secretion was not affected in fetal pituitary cultures. In cultures of eight GH-secreting adenomas, octreotide was superior to PTR-3173 in suppressing GH from two adenomas, PTR-3173 was more potent in three other tumors, and three adenomas did not respond significantly to either analog. PTR-3173 suppressed PRL in several mixed GH-PRL adenomas. In conclusion, PTR-3173, a novel SS analog with a unique SSTRs binding combination, is a potent in vitro suppressor of human GH. Combining this inhibitory effect with the lack of effect on insulin secretion, it is suggested that PTR-3173 may be clinically useful for the treatment of acromegaly.
Asunto(s)
Hormona de Crecimiento Humana/antagonistas & inhibidores , Receptores de Somatostatina/metabolismo , Somatostatina/análogos & derivados , Somatostatina/metabolismo , Adenoma/metabolismo , Células Cultivadas , Hormona de Crecimiento Humana/metabolismo , Humanos , Proteínas de la Membrana , Octreótido/farmacología , Hipófisis/metabolismo , Neoplasias Hipofisarias/metabolismo , Prolactina/antagonistas & inhibidores , Prolactina/metabolismo , Células Tumorales CultivadasRESUMEN
Neuronavigation has become a standard technique in many neurosurgical procedures where its use allow better positioning of the craniotomy flap, precise targeting of lesions, and better anatomical orientation. However, the imaging used in such procedures is acquired preoperatively and thus, cannot project the dynamic changes that occur during surgery and result in many cases in significant brain shift and decreased accuracy. Recent technological developments have yielded a variety of MRI machines that can be used intraoperatively and provide the surgeon with updated images, integrated navigation capabilities, full compensation for brain shifts, and the ability to assess the extent of resection of the lesion. The concepts behind such technologies vary from one manufacture to another resulting in systems that vary in complexity, ease of use, spatial demands, and cost. In this chapter we review our experience with two intraoperative MRI systems used in a variety of neurosurgical procedures: the GE Signa SP System and the Odin PoleStar System.
Asunto(s)
Neoplasias Encefálicas/cirugía , Glioma/cirugía , Procesamiento de Imagen Asistido por Computador/instrumentación , Imagen por Resonancia Magnética/instrumentación , Neuronavegación/instrumentación , Neoplasias Hipofisarias/cirugía , Biopsia/instrumentación , Encéfalo/patología , Encéfalo/cirugía , Neoplasias Encefálicas/patología , Craneotomía/instrumentación , Diseño de Equipo , Glioma/patología , Humanos , Aumento de la Imagen , Neoplasias Hipofisarias/patología , Complicaciones Posoperatorias/etiología , Estudios Retrospectivos , Evaluación de la Tecnología BiomédicaRESUMEN
We report a unique case of a 28-yr-old woman with a gonadotroph adenoma secreting FSH, presented with ovarian hyperstimulation, without elevation of serum estradiol. She presented with abdominal pain and large ovaries (both 10 cm in diameter) with multiple follicular cysts shortly after discontinuing oral contraceptive pills. She had a supranormal PRL level of 71 microg/liter (normal, <20), FSH of 8.4-9.2 IU/liter (normal for follicular phase, 2.4-10), LH of 0.01 IU/liter (normal, 1.6-9.3), estradiol of 108 pmol/liter (normal for follicular phase, 80-790), and free alpha-subunit level of 0.11 microg/liter (normal, <1.8). A nuclear magnetic resonance study revealed invasive pituitary macroadenoma, 30 mm in diameter. Dopamine agonist (cabergoline) treatment normalized serum PRL but had no affect on FSH levels. A transsphenoidal surgery was performed, and most of the adenoma was resected. One month after surgery the patient resumed menstruation, and the hormonal profile included serum FSH of 6.3 IU/liter, LH of 2.1 IU/liter, estradiol of 156 pmol/liter, and PRL of 10 microg/liter. The excised adenoma tissue exhibited intense immunostaining for FSH and secreted this hormone to culture medium. Stimulation with TRH (both in vivo preoperatively and in vitro study of the excised tumor) had no effect on FSH secretion from the adenoma. Estradiol did not suppress FSH release from cultured adenoma cells. Patient serum samples showed significant FSH bioactivity when tested in a human granulosa cell line. This case is remarkable because the ovarian hyperstimulation related to the FSH-secreting adenoma was not associated with high levels of serum estradiol, probably due to insufficient LH production by the normal pituitary. Thus, it supports the two-cell, two-gonadotropin theory, that both FSH and LH are necessary for normal ovarian estrogen production.
Asunto(s)
Adenoma/fisiopatología , Estradiol/sangre , Hormona Folículo Estimulante/metabolismo , Neoplasias Hipofisarias/fisiopatología , Dolor Abdominal , Adenoma/sangre , Adenoma/diagnóstico , Adenoma/cirugía , Adulto , Femenino , Hormona Folículo Estimulante/sangre , Humanos , Hormona Luteinizante/sangre , Imagen por Resonancia Magnética , Quistes Ováricos/diagnóstico por imagen , Quistes Ováricos/etiología , Síndrome de Hiperestimulación Ovárica/sangre , Síndrome de Hiperestimulación Ovárica/etiología , Síndrome de Hiperestimulación Ovárica/fisiopatología , Neoplasias Hipofisarias/diagnóstico , Neoplasias Hipofisarias/patología , Neoplasias Hipofisarias/cirugía , Hormona Liberadora de Tirotropina , Resultado del Tratamiento , UltrasonografíaRESUMEN
Convection-enhanced drug delivery (CEDD) is a novel approach to enhance the delivery of drugs directly into brain tumors. We have used diffusion-weighted MRI (DWMRI) to monitor the effects of intratumoral CEDD in three brain tumor patients treated with Taxol. Clear changes in the images and the water diffusion parameters were observed shortly after the initiation of treatment. Initially, a bright area corresponding to decreased diffusion appeared, followed by the appearance of a dark area of increased diffusion within the bright area. The time to appearance of the dark area varied among the patients, suggesting different response rates. In this work, we have demonstrated the feasibility of using DWMRI as a noninvasive tool to achieve unique early tissue characterization not attainable by other conventional imaging methods.
Asunto(s)
Antineoplásicos Fitogénicos/administración & dosificación , Neoplasias Encefálicas/tratamiento farmacológico , Sistemas de Liberación de Medicamentos , Glioma/tratamiento farmacológico , Paclitaxel/administración & dosificación , Neoplasias Encefálicas/patología , Convección , Difusión , Glioma/patología , Humanos , Imagen por Resonancia Magnética/métodos , Monitoreo Fisiológico/métodos , Recurrencia Local de Neoplasia/tratamiento farmacológico , Agua/metabolismoRESUMEN
The hypothalamic peptide PRL-releasing peptide (PrRP) has recently been cloned and identified as a ligand of an orphan pituitary receptor that stimulates in vitro PRL secretion. PrRP also induces PRL release in rats in vivo, especially in normal cycling females. However, no information on the effects of PrRP in the human is available. To elucidate the role of PrRP in regulating human anterior pituitary hormones, we used human PrRP-31 in primary cultures of human pituitary tissues, including fetal (20--27 weeks gestation) and normal adult pituitaries, as well as PRL- and GH-secreting adenomas. PrRP increased PRL secretion from human fetal pituitary cultures in a dose-dependent manner by up to 35% (maximal effect achieved with 10 nM), whereas TRH was slightly more potent for PRL release. Coincubation with estradiol resulted in enhanced fetal PRL response to PrRP, and GH release was only increased in the presence of estradiol. Although PRL secretion from PRL-cell adenomas was not affected by PrRP, PrRP induced PRL release from cultures of a GH-cell adenoma that cosecreted PRL. PrRP enhanced GH release in several GH-secreting adenomas studied by 25--27%, including GH stimulation in a mixed PRL-GH-cell tumor. These results show for the first time direct in vitro effects of PrRP-31 on human pituitary cells. PrRP is less potent than TRH in releasing PRL from human fetal lactotrophs and is unable to release PRL from PRL-cell adenomas in culture, but stimulated GH from several somatotroph adenomas. Thus, PrRP may participate in regulating GH, in addition to PRL, in the human pituitary.
Asunto(s)
Adenoma/metabolismo , Hormona de Crecimiento Humana/metabolismo , Hormonas Hipotalámicas/farmacología , Neuropéptidos/farmacología , Hipófisis/metabolismo , Neoplasias Hipofisarias/metabolismo , Prolactina/metabolismo , Adulto , Células Cultivadas , Feto , Humanos , Hipófisis/citología , Hormona Liberadora de ProlactinaRESUMEN
OBJECTIVE: Transsphenoidal surgery is the preferred treatment modality for growth hormone (GH)-secreting pituitary adenomas. In many series, the reported postoperative remission is based mainly on achievement of GH levels less than 2 ng/ml. Strict criteria for insulin-like growth factor I normalization and even lower GH levels (<1 ng/ml) are now suggested to define cure of acromegaly, but the evidence does not yet support such low GH levels in epidemiological follow-up. We analyzed our postoperative results in a large cohort of patients with acromegaly. METHODS: Ninety-eight patients harboring GH-secreting adenomas (46 microadenomas and 52 macroadenomas) underwent transsphenoidal surgery between 1990 and 1999. Ninety-one patients were operated for the first time, and 12 patients underwent reoperations because of previous surgical failure (7 had undergone surgery elsewhere previously). Biochemical remission was defined as a repeated fasting or glucose-suppressed GH level of 2 ng/ml or less, and a normal insulin-like growth factor I level. RESULTS: Remission was achieved in 74% of all patients after one operation, including 84% of patients with microadenomas and 64% of patients with macroadenomas. Seventy-three percent of patients with macroadenomas 11 to 20 mm in size achieved remission, as compared with a 20% remission rate for patients with adenomas larger than 20 mm. Patients with preoperative random GH levels lower than 50 ng/ml had a better outcome (85% remission), whereas GH greater than 50 ng/ml was associated with remission in 30% of the patients. Only one of the patients (8%) with postoperative active disease who underwent a second operation achieved remission. Recurrence was rare (one patient), and all failed surgical attempts could be detected during the immediate postoperative evaluation. CONCLUSION: On the basis of strict postoperative GH and insulin-like growth factor I criteria to define remission, our series demonstrates the efficacy of transsphenoidal surgery for acromegalic patients with microadenomas and noninvasive macroadenomas. However, patients with large adenomas (>20 mm) and preoperative GH greater than 50 ng/ml have a poor prognosis and require adjunctive medical or radiation therapy to control GH hypersecretion.
Asunto(s)
Acromegalia/cirugía , Procedimientos Neuroquirúrgicos , Acromegalia/fisiopatología , Adulto , Anciano , Estudios de Cohortes , Glándulas Endocrinas/fisiopatología , Femenino , Estudios de Seguimiento , Hormona de Crecimiento Humana/sangre , Humanos , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias , Periodo Posoperatorio , Inducción de Remisión , Hueso Esfenoides/cirugíaRESUMEN
Adequate analgesia and sedation with adequate respiratory and hemodynamic control are needed during brain surgery in awake patients. In this study, a protocol using clonidine premedication, intraoperative propofol, remifentanil, and labetalol was evaluated prospectively in 25 patients (aged 50 +/- 16). In all but one patient, no significant problems regarding cooperation, brain swelling, or loss of control were noticed, and it was not necessary to prematurely discontinue any of the procedures. One patient, who was uncooperative and hypertensive, became apneic with increasing sedation, and needed a laryngeal mask airway inserted. Patients were hemodynamically stable; elevated systolic blood pressure (>or= 150 mm Hg) was measured infrequently, and there were no events of significant hypotension, tachycardia, or bradycardia. Events of hypoxemia (SAO2 Asunto(s)
Analgésicos Opioides
, Anestesia Intravenosa/métodos
, Anestésicos Intravenosos
, Neoplasias Encefálicas/cirugía
, Craneotomía
, Monitoreo Intraoperatorio/métodos
, Piperidinas
, Propofol
, Vigilia
, Analgésicos Opioides/administración & dosificación
, Anestésicos Intravenosos/administración & dosificación
, Presión Sanguínea
, Mapeo Encefálico
, Electrocardiografía
, Femenino
, Hemodinámica
, Humanos
, Complicaciones Intraoperatorias/clasificación
, Complicaciones Intraoperatorias/epidemiología
, Masculino
, Persona de Mediana Edad
, Oximetría
, Piperidinas/administración & dosificación
, Propofol/administración & dosificación
, Remifentanilo
, Mecánica Respiratoria
RESUMEN
BACKGROUND: The transfer of therapeutic genes into malignant brain tumors has been the subject of intense preclinical and clinical research in recent years. Most approaches have used direct intratumoral placement of a variety of vectors and genes, such as retroviruses or adenoviruses carrying drug-susceptibility genes, modified replication-competent herpes virus, and several vectors carrying tumor suppressor genes such as the p53 gene. However, clinical results have so far been disappointing, mainly due to the limited ability to effectively distribute the genetic material into the target cell population. Accordingly, alternative delivery approaches into the central nervous system, e.g., intravascular, are under investigation. Genetic vectors administered intravascularly are unlikely to penetrate the blood-brain barrier and transfer a gene into brain or tumor parenchyma. However, intravascular delivery of vectors may target endothelial cells lining the blood vessels of the brain. Since endothelial cells participate in a variety of physiological and pathological processes in the brain, their modulation by gene transfer may be used for a variety of therapeutic purposes. Angiogenically stimulated endothelial cells within tumors replicate rapidly and hence may become targets for retroviral-mediated gene transfer. OBJECTIVE: To assess the anti-tumor effect of transferring a drug-susceptibility gene into endothelial cells of the tumor vasculature. METHODS: As a model for this approach we delivered concentrated retroviral vectors carrying a drug-susceptibility gene via the internal carotid artery of rats with malignant brain tumors. The safety and efficacy of this approach, without and with subsequent treatment with a pro-drug (ganciclovir), was evaluated. RESULTS: No acute or long-term toxicity was observed after intraarterial infusion of the vector. Treatment with ganciclovir resulted in variable hemorrhagic necrosis of tumors, indicating preferential transduction of the angiogenically stimulated tumor vasculature. This was accompanied by severe toxicity caused by subarachnoid hemorrhage and intracerebral hemorrhage in vascular territories shared by the tumor and adjacent brain. CONCLUSION: The data indicate that endothelial cells can be targeted by intraarterial delivery of retroviral vectors and can be used for devising new gene therapy strategies for the treatment of brain tumors.
Asunto(s)
Neoplasias Encefálicas/terapia , Terapia Genética/métodos , Vectores Genéticos/farmacología , Gliosarcoma/terapia , Animales , Neoplasias Encefálicas/patología , Modelos Animales de Enfermedad , Femenino , Gliosarcoma/patología , Infusiones Intraarteriales , Masculino , Ratas , Ratas Endogámicas F344 , Retroviridae , Sensibilidad y Especificidad , Tasa de Supervivencia , Resultado del TratamientoRESUMEN
OBJECTIVE: Preliminary clinical experience with a novel, compact, intraoperative magnetic resonance imaging (MRI)-guided system that can be used in an ordinary operating room is presented. DESCRIPTION OF INSTRUMENTATION: The system features an MRI scanner integrated with an optical and MRI tracking system. Scanning and navigation, which are operated by the surgeon, are controlled by an in-room computer workstation with a liquid crystal display screen. The scanner includes a 0.12-T permanent magnet with a 25-cm vertical gap, accommodating the patient's head. The field of view is 11 x 16 cm, encompassing the surgical area of interest. The magnet is mounted on a transportable gantry that can be positioned under the surgical table when not in use for scanning, thus rendering the surgical environment unmodified and allowing the use of standard instruments. The features of the integrated navigation system allow flap planning and intraoperative tracking based on updated images acquired during surgery. OPERATIVE TECHNIQUE: Twenty patients with brain tumors were surgically treated using craniotomy or trans-sphenoidal approaches. One patient underwent conscious craniotomy with cortical mapping, and two underwent electrocorticography. EXPERIENCE AND RESULTS: Planning was accurate. Resection control images were obtained for all patients during surgery, with precise localization of residual tumor tissue. There were no surgical complications related to the use of the system. CONCLUSION: This intraoperative MRI system can function in a normal operating room modified only to eliminate radiofrequency interference. The operative environment is normal, and standard instruments can be used. The scanning and navigation capabilities of the system eliminate the inaccuracies that may result from brain shift. This novel type of intraoperative MRI system represents another step toward the introduction of the modality as a standard method in neurosurgery.
Asunto(s)
Encefalopatías/cirugía , Neoplasias Encefálicas/cirugía , Procesamiento de Imagen Asistido por Computador/instrumentación , Imagen por Resonancia Magnética/instrumentación , Quirófanos , Técnicas Estereotáxicas/instrumentación , Equipo Quirúrgico , Interfaz Usuario-Computador , Adolescente , Adulto , Anciano , Encéfalo/patología , Encéfalo/cirugía , Encefalopatías/diagnóstico , Neoplasias Encefálicas/diagnóstico , Niño , Preescolar , Craneotomía/instrumentación , Diseño de Equipo , Femenino , Humanos , Masculino , Persona de Mediana EdadRESUMEN
The authors present their initial experience with a compact open magnetic resonance (MR) image-guided system, (PoleStar N-10, Odin Medical Technologies, Yokneam, Israel) used in a standard operating room, modified for radio frequency (RF) shielding. The low intensity of the magnetic field (0.12T), and the ability to lower the magnet from the operative field during surgery allows for an almost routine surgical procedure, in addition to the benefits of using intraoperative MR imaging. Although an MR compatible anesthesia machine and monitoring system are used, the system offers anesthesiologists access to the patient at all times during the procedure, and the ability to use conventional surgical equipment, syringe pumps, and warming devices. Propofol and remifentanil, used for maintaining anesthesia, allow early extubation and neurological evaluation at the end of surgery. Electrocorticographic monitoring can be used during surgery for epilepsy, and awake craniotomy can be performed. More experience with this new imaging system is required to assess its influence on clinical decision making and outcome.
Asunto(s)
Anestesia , Imagen por Resonancia Magnética , Procedimientos Neuroquirúrgicos , Adolescente , Adulto , Anciano , Niño , Preescolar , Femenino , Humanos , Procesamiento de Imagen Asistido por Computador , Masculino , Persona de Mediana Edad , Monitoreo IntraoperatorioRESUMEN
UNLABELLED: Changes in arterial blood pressure induced by mechanical ventilation allow assessment of cardiac preload. In this study, stroke volume variation (SVV), which is the percentage change between the maximal and minimal stroke volumes (SV) divided by the average of the minimum and maximum over a floating period of 30 s, continuously displayed by the PiCCO continuous cardiac output monitor, was evaluated as a predictor of fluid responsiveness. Fifteen patients undergoing brain surgery were included. During surgery, graded volume loading was performed with each volume loading step (VLS) consisting of 100 mL of 6% hydroxyethylstarch given for 2 min. Successive responsive VLSs were performed (increase in SV > 5% after a VLS) until a change in SV of < 5 % was reached (nonresponsive). A total of 140 VLSs were performed. Responsive and nonresponsive VLSs differed in their pre-VLS values of systolic blood pressure, SV, and SVV, but not in the values of heart rate and central venous pressure. By using receiver operating characteristic analysis, the area under the curve for SVV (0.870, 95% confidence interval [CI]: 0.809 to 0.903) was statistically more than those for central venous pressure (0.493, 95% CI: 0.397 to 0.590, P = 7 x 10(-10)), heart rate (0.593, 95% CI: 0.443 to 0.635, P = 5.7 x 10(-10)), and systolic blood pressure (0.729, 95% CI: 0.645 to 0.813, P: = 4.3 x 10(-3)). An SVV value of 9.5% or more, will predict an increase in the SV of at least 5% in response to a 100-mL volume load, with a sensitivity of 79% and a specificity of 93%. IMPLICATIONS: Stroke volume variation may be used as a continuous preload variable and in combination with the continuously measured cardiac output, defining on-line the most important characteristics of cardiac function, allowing for optimal fluid management.
Asunto(s)
Encéfalo/cirugía , Fluidoterapia , Procedimientos Neuroquirúrgicos , Volumen Sistólico/fisiología , Anciano , Presión Venosa Central/fisiología , Femenino , Hemodinámica/fisiología , Humanos , Derivados de Hidroxietil Almidón/uso terapéutico , Masculino , Persona de Mediana Edad , Sustitutos del Plasma/uso terapéutico , Valor Predictivo de las PruebasRESUMEN
OBJECT: The use of radiosurgery in the treatment of acoustic neuromas has increased substantially during the last decade. Most published experience relates to the use of the gamma knife. In this report, the authors review the methods and results of linear accelerator (LINAC) radiosurgery in 44 patients with acoustic neuromas who were treated between 1993 and 1997. METHODS: Computerized tomography scanning was selected as the stereotactic imaging modality for target definition. A single, conformally shaped isocenter was used in the treatment of 40 patients; two or three isocenters were used in four patients who harbored very irregular tumors. The radiation dose directed to the tumor border was the only parameter that changed during the study period: in the first 24 patients who were treated the dose was 15 to 20 Gy, whereas in the last 20 patients the dose was reduced to 11 to 14 Gy. After a mean follow-up period of 32 months (range 12-60 months), 98% of the tumors were controlled. The actuarial hearing preservation rate was 71%. New transient facial neuropathy developed in 24% of the patients and persisted to a mild degree in 8%. Radiation dose correlated significantly with the incidence of cranial neuropathy, particularly in large tumors (> or = 4 cm3). CONCLUSIONS: Single-isocenter LINAC radiosurgery proved to be an effective treatment for acoustic neuromas in this series, with results that were comparable with those reported for gamma knife radiosurgery and multiple isocenters.
Asunto(s)
Neuroma Acústico/cirugía , Aceleradores de Partículas , Radiocirugia/instrumentación , Adulto , Anciano , Relación Dosis-Respuesta en la Radiación , Enfermedades del Nervio Facial/etiología , Femenino , Audición , Humanos , Masculino , Persona de Mediana Edad , Neuroma Acústico/diagnóstico , Complicaciones Posoperatorias , Periodo Posoperatorio , Técnicas Estereotáxicas , Tomografía Computarizada por Rayos X , Resultado del Tratamiento , Enfermedades del Nervio Trigémino/etiologíaRESUMEN
We report a case of acromegaly with relatively low GH secretion in a patient with GH-secreting pituitary macroadenoma. The 44-year-old male patient presented with left temporal hemianopsia and characteristic acromegalic face, but had relatively low baseline and post-glucose GH levels. IGF-1 and IGFBP-1 were elevated. Transsphenoidal surgery did not achieve clinical or biochemiacl remission, and the patient still had elevated IGF-1 levels with low GH. Histological examination of the resected tumor revealed a pituitary adenoma stained weakly for GH. The patient was treated then with monthly injections of Sandostatin-LAR, with clinical improvement and suppression of IGF-I to the normal range. This is a rare case of acromegaly without elevated GH levels, and good response to treatment with somatostatin analog, as expected in classical GH-secreting pituitary adenomas.
Asunto(s)
Acromegalia/tratamiento farmacológico , Acromegalia/metabolismo , Adenoma/tratamiento farmacológico , Hormona de Crecimiento Humana/metabolismo , Octreótido/uso terapéutico , Neoplasias Hipofisarias/tratamiento farmacológico , Acromegalia/complicaciones , Acromegalia/patología , Adenoma/complicaciones , Adenoma/metabolismo , Adenoma/patología , Adulto , Antineoplásicos Hormonales/administración & dosificación , Antineoplásicos Hormonales/farmacología , Antineoplásicos Hormonales/uso terapéutico , Hormona de Crecimiento Humana/sangre , Humanos , Inmunohistoquímica , Proteína 3 de Unión a Factor de Crecimiento Similar a la Insulina/sangre , Factor I del Crecimiento Similar a la Insulina/metabolismo , Imagen por Resonancia Magnética , Masculino , Octreótido/administración & dosificación , Octreótido/farmacología , Neoplasias Hipofisarias/complicaciones , Neoplasias Hipofisarias/metabolismo , Neoplasias Hipofisarias/patología , Prolactina/sangre , Visión Ocular/efectos de los fármacos , Visión Ocular/fisiologíaRESUMEN
Intratumoral hemorrhage as the presenting symptom of spinal tumors is rare. The authors describe a patient who presented with rapidly progressing paraplegia 24 hours after sustaining a minor traumatic injury of the thoracic spine. Radiological evaluation demonstrated a low-thoracic intradural tumor that was resected and found to be a neurinoma in which severe intra- and peritumoral hemorrhage was revealed. The radiological, surgical, and pathological findings are presented and discussed.
Asunto(s)
Hemorragia/etiología , Neurilemoma/irrigación sanguínea , Neoplasias de la Médula Espinal/irrigación sanguínea , Traumatismos Vertebrales/complicaciones , Accidentes por Caídas , Hemorragia/complicaciones , Humanos , Laminectomía , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Neurilemoma/diagnóstico , Neurilemoma/patología , Neurilemoma/cirugía , Paraplejía/etiología , Neoplasias de la Médula Espinal/diagnóstico , Neoplasias de la Médula Espinal/patología , Neoplasias de la Médula Espinal/cirugíaRESUMEN
OBJECTIVES: Prevertebral abscess formation is an uncommon occurrence following cervical spine fusion surgery. Abscesses may present early or in a delayed fashion and require surgical drainage and long-term antibiotic treatment. The issues of osteomyelitis and the need for plate removal remain unresolved. STUDY DESIGN: A case series of six tetraplegic patients admitted for rehabilitation to the Chaim Sheba Medical Center (Tel Hashomer, Israel) is presented. METHODS: Five patients were trauma patients; one patient underwent repeated procedures and irradiation for tumor of the cervical spine. All patients developed prevertebral abscesses after a mean period of 30 days from their fusion surgery. Computed tomography scan was used in all patients to establish the diagnosis and define the extent of the infective process. All patients underwent one or more drainage procedures. The plate was removed in two patients at 1 and 4 months. RESULTS: Infection completely resolved in four patient and was refractory in one patient with malignant tumor, and a chronic small fistula remained in one case. Staphylococcus aureus was the main infective organism, but mixed infections were the rule. Even for a protracted course of infection, no significant osteomyelitis was encountered. CONCLUSIONS: Abscess formation after instrumentation of the neck may be more common than formerly recognized. Despite the prolonged course of disease and treatment, osteomyelitis is not a major concern. There is no automatic indication for plate removal to control infection, although plating may be safely removed after 10 to 12 weeks if the neck is explored and the cervical spine is stable. A high index of suspicion is warranted, and early recognition and diagnosis, prompt surgical drainage under general anesthesia, and long-term antibiotic treatment are key for eradication of the infective process. Prophylactic antibiotics may be of value. Meticulous antisepsis and surgical technique should be maintained to reduce the incidence of these severe complications.